

Subject Index

- Abelson virus, 425
 - infection of bone marrow cultures with, 226, 491
 - in vitro transformation of B-Lymphocytes by, 489
- Adenocarcinoma, 469
 - immunisation against, with FLV, 475
 - immunotherapy of, 469
- Acid phosphatase
 - in CFU-C, 211
 - in leukemic cells, 107, 336
- Adenosin deaminase, 141
 - inhibitor of, 142
 - in leukemic cells, 141
- Adriamycin
 - therapy with, in ALL, 100
 - in AML, 89, 93
- Agar colony technique, 181, 211
- Agouti allele, 474
- ALL, 25, 99, 115
 - cellmembran antigen in, 336, 348, 356, 417
 - CFU-C in, 133, 172, 212
 - classification of, 32, 99, 336
 - epidemiology of, 37
 - treatment of, 26, 30, 99, 115, 117, 153, 159
- Alpha-naphthylacetate-esterase
 - in CFU-C, 211
 - in Makrophages, 172
- AML, 7
 - cellmembran antigen in, 339, 356
 - CFU-C in, 133, 172, 212
 - continuous cell line of, 220
 - CSF in, 201
 - differentiation in vitro of, 17
 - DNA repair defect in, 40
 - immunotherapy in, 79
 - inhibition of normal CFU-C growth by, 186
 - microenviromental influences with bone marrow in, 199
 - prediction of therapeutic responseto, 93
 - surface immunglobulins in, 17, 336
 - T-cell function in, 381
- ANLL, see also AML and Leukemia
 - chromosome abnormalities in, 46
- Anthracycline
 - treatment with, 157
- Antibodies
 - antitumor, 407
 - degradation by tumor derived lysosomal extracts, 407, 420
 - in human serum against type-C viruses, 390, 396
 - monoclonal, 365
 - against HLA, 360
 - response to BLV, 450
 - to FLV, 458
 - to FOCMA, 458
- Antigen, see also cell surface antigen
 - early embryonic F₉, 582
- Antisera, see antibodies
- Aplastic anemia
 - transplantation in, 77
- 1-β-D-arabinofuranosyl-cytosin, see cytosin arabinosid
- Ara-CTP
 - in leukemic cells, 94, 139
- Asparaginase
 - treatment with, 30, 100
- Ataxia-telangiectasic, 39, 49
- Avian
 - carcinoma virus (MH2), 241
 - erythroblastosis virus (AEV), 429
 - gene products of, 431, 437
 - target cells for, 431, 437
 - transformation of hematopoietic cells by, 429
 - leukosis virus, 439
 - RIP reactive human antibodies against, 396
 - myelocytomatosis virus (MC29), 241, 429
 - gene products of, 241, 431, 437
 - target cells for, 430, 433
 - transformation of hematopoietic cells, 429
 - sarcoma virus, 261
 - transforming gen product of, 261
 - tumor virus RNA, 242
 - transforming genes of 242-259
- Baboon endogenous type-C virus, 11
 - in human leukemic cells, 558

- RIP for reactive human antibodies against, 396
- BCG treatment, see immunotherapy
- B-cells, 327, see also Lymphocytes
 - EBV and, 238
 - surface markers of, in leukemia, 108
 - transformation by Abelson Virus, 489
- Benzene and leukemia, 38
- BFU-E, 191, 207
 - leukemic inhibition of, 186
 - in polycythemia vera, 207
- Bloom's syndrom, 39, 49
- B-lymphocytes, see B-cells
- Bone marrow
 - cocultivation for detection of oncornaviruses, 497
 - culture, continuous, 177, 223
 - – infected with C-type RNA virus, 177, 225, 231, 491
 - histopathology of, 58
 - transplantation, 71
 - – autologous, 92
 - Bovine leukemia, 440, 445
 - epidemiology of, 449
 - virus 446
 - – antibody response to, 451
 - – genom of, 446
 - – proteins of, 447
- Cat leukemia, 454, see also FeLV
- Cell differentiation
 - cellmembran antigens in, 338, 349
 - molecular biology of, 327
 - virus related genes in, 329
- Cell hybrids
 - of human cells with chinese hamster ovary cells, 303
 - of mouse cells with chinese hamster cells, 563
 - human markers in, 316
 - production of monoclonal antibodies in, 365, 420
 - selective loss of chromosomes in, 313, 564
 - of teratocarcinoma and SV40 transformed mouse fibroblasts, 583
- Cell-mediated immunity
 - in immunotherapy, 84
- Cell membrane, see cell surface
- Cell surface antigen
 - in ALL, 32, 101, 336
 - in bloodcell differentiation, 338
 - genetic analysis of, 313
 - in leukemia, 133, 160
 - monoclonal antibodies against, 365
- CFU-C, 181, 191, 200, 217
 - cytochemistry of, 211
 - G-6-PD isoenzyme in, inhibition of, 55
 - – by anti-B cell sera, 340, 349
 - – by leukemia specific activity, 175, 182, 186
 - – by PG, 172
 - in leukemia, 133, 160, 176, 212, 217
- CFU-E, 206
- CFU-S, 181, 191, 223
 - transformation of, 225
- Chemoimmunotherapy, 82
- Chemotherapy
 - combination, 26, 89, 93, 100, 117, 164
 - drug metabolism in, 98, 139
 - target cells for, 96
- Chromosomes
 - abnormalities in leukemia, 39, 43, 47, 60, 195
 - banding technique, 44
 - for human cell surface antigens, 314
 - rearrangements of, 508
- CLL
 - epidemiology of, 37
- CML
 - chromosome abnormalities in, 43, 65
 - clinic of, 43, 65
 - G-6-PD isoenzymes in, 53, 193, 205
 - Histopathology of, 59
- CNS leukemia, 26, 115, 159
 - prophylaxis of, 26, 99, 115, 159
 - relaps of, 119, 159
- 2'-deoxy-coformycin
 - antilymphocytic effect of, 142
 - inhibitor of ADA, 142
- Common ALL antigen, 33, 102, 108, 337, 347, 353
 - expression in MOLT-4 cell line, 342, 347, 362
 - preparation of, 354
 - in serum of leukemic patients, 357
- Complement (C₃) receptors
 - and Epstein Barr virus, 237
 - in B-, T-, and non B-, T-cells, 238
- CSA see CSF
- CSF, 171, 181
 - in AML, 201
 - independent colony forming cells, 488
 - inhibition by lactoferrin, 173
 - production in macrophages, 172, 201
- C-type virus, see also virus
 - antisera against, 118, 402
 - DNA fragments, 561
 - endogenous, and immunsystem, 413, 418
 - expression in human, 401
 - human serological reactivity with, 392, 395, 418
 - M-7 from papiocynocephalus, identical to, 502
- Cyclophosphamide, 159
- Cytochemistry
 - in ALL, 102

- of CFU-C, 211
- Cytidine deaminase, 139
- Cytomegalovirus (CMV)
 - in transplantation, 74
- Cytosine arabinosid, 93, 139, 157
 - metabolism of, 139
 - phosphorylation in leukemic cells, 93
 - retention in leukemic cells, 93, 157
- Daunorubicine**
 - in treatment of AML, 89
- Diffusion chamber, 182, 217
 - differentiation of leukemic cells in, 218
 - transmembrane effect in, 183, 188
- Dimethylsulfoxide (DMSO)
 - differentiation of human leukemic cells by, 18
 - of Friend leukemic cells by, 286, 298, 304, 308
- DNA**
 - fluorescence in leukemic cells, 96
 - loop, 507
 - of human leukemic cells, transfection with, 484
 - provirus, 423
 - viral, in human leukemic cells, 483
- Down's syndrom, 39
- Electron microscopy of leukemic cells,** 109
- Epidemiology**
 - of cat leukemia, 456
 - of human leukemia, 37
- Epstein-Barr virus, 237, 523
- Erythropoietin
 - stimulation of DFU-E and CFU-E with, 207, 309
 - undependent stem cells, 309
- Evolution**
 - gene rearrangement in, 507
 - of R-plasmids, 509
- Fanconi's anemia,** 39, 49
- FeLV, 8, 441
 - antibodies in human sera against, 396
 - anti-sera, 402
 - fingerprint analysis of, 544
- Fingerprint analysis of C-type virus RNA, 246, 254, 532, 534, 539, 541, 542, 544, 547
- FOCMA, 9, 441, 459
 - and immune surveillance, 463
- Friend leukemia cells, 286
 - DMSO stimulated, 286, 298, 304
 - effect of interferon on, 308
 - fractions, translational inhibitors from, 286, 327
 - protein synthesis in, 298, 304
- Friend leukemia virus, 425
 - effect of interferon on, 308
 - immunisation with, against AD755a tumor, 475
 - infection of bone marrow cultures with, 177, 224
- Gag**
 - gen, 425
 - proteins, in vitro synthesis of, 273
- Gene**
 - antibiotica resistance, 509
 - of BLV, 446
 - of MC29, 247
 - of MH₂, 247
 - onc, 258, 426, 436
 - product, transforming, of avian tumor viruses, 257, 261, 271, 328, 329, 425, 435
 - reactivation of persisting, 523
 - src, 241, 425
 - transpose of, 509
- Genetic**
 - analysis of human cell surface structures, 313, 368
 - diseases, transplantation in, 77
 - factors, in leukemia, 7
 - locus to immune response against AD755a tumor cells, 473
- Gibbon ape leukemia virus (GaLV),** 9
 - endogenous human DNA sequences of, 555
 - fingerprint analysis of, 541
 - in human cells, 553
 - proviral DNA sequences of, 555
- G-6-PD isoenzymes, 53, 195, 205
 - in CFU-C, 195, 208
 - in CFU-E, 206
 - in CML, 53, 195, 205, 341
 - in myelofibrosis, 57, 207
 - in polycythemia vera, 56, 195, 207
- Graft versus host disease, 73
- Hemopoietic differentiation and viral genes,** 435
- Hematopoiesis**
 - leukemic inhibition of, 181, 435
- Herpes virus, 525
- Hetroduplex molecules, 516
- Histocompatibility complex, see HLA
- HLA, 370, 377
 - monoclonal antibodies against, 367
 - system, 72
 - T-cell response against, 370
- HL-23V, 12
 - anti-sera, 402
 - DNA, transfection assays with, 484
 - fingerprint analysis of, 542
 - infection of bone marrow cultures with, 168
- Hodgkin's disease
 - herpes zoster in patients with, 524

- Ia-antigen**, 337
 – expression on myeloid stem cells, 340
 – in lymphoid cell differentiation, 338
- Immune response**
 – to AD755a tumor cells, 469
 – to BLV, 450
 – expression of endogenous viral antigens in, 413
 – to FeLV, 457
 – to FOCMA, 458
- Immunological**
 – classification of ALL, 32, 103
 – identification of plasma cells in CFU-C, 212
 – protection against C-type virus by human and primate complement, 502
- Immunosuppression**
 – by antiserum against endogenous C-type virus, 414
 – in bone marrow transplantation, 72
- Immunotherapy**
 – of Adenocarcinoma AD755a, 469
 – of cat leukemia, 463
 – of human leukemia, 79, 379
 – MER in, 82
- Initiation factor in protein synthesis**, 283
- Insertion sequences (IS)**
 – in bacteria, 48, 507
- Integration of C-type viral DNA fragments**, 561
- Interferon**, 291
 – activation of protein kinase by, 292
 – antiviral activity of, 291
 – effect on Friend leukemia cell differentiation, 307
 – induced inhibition of proteinsynthesis, 292
 – induced synthesis of 2-5A, 292
- Interstitial pneumonitis in transplantation**, 74
- Irradiation**
 – craniospinal-meningeal, 26, 99
- Kirsten sarcoma virus**
 – infection of bone marrow culture with, 177
- Lactoferrin**
 – inhibition of CSF production by, 175, 325
- Leukemia**
 – antigens, 101, 336, 348, 353, 377, 417
 – benzene and, 38
 – bovine, 440
 – cell markers in, 32, 101, 107, 133, 160, 336, 350
 – CFU-C in, 133, 214
 – clonal origin of, 49, 53, 133, 160
 – cluster, 39
 – epidemiology of, 37
 – feline, 441, 454
 – genetic factors in, 7, 39, 49
 – hepatosplenomegaly in, 102
 – human, oncoviruses in, 493
 – infectious, in domestic animals, 439
 – in vitro induction of, 223
 – radiation, and, 7, 37
 – T-cell response to, 379
 – terminale deoxynucleotidyl transferase in, 112, 125, 133, 158, 166
 – transplantation in, 74
 – virus negative, 442, 454
- Leukemic cell**
 – acid phosphatase in, 111
 – antigens, related to C-type viruses in, 403
 – cytochemistry of, 102, 107
 – cytotoxic T-cell response against, 373, 379
 – differentiation of, in DC, 219
 – induced by in vitro infection of bone marrow with FLV, 225, 231
 – inhibition of BFU-E and CFU-C growth by, 175, 182, 186
 – lines, 341, 347
 – cALL antigen expression in, 341, 347
 – myeloperoxidase of, 107
 – phenotypes and hemopoietic differentiation, 342, 351
 – ribonucleotide pools in, 141
 – serum against, 33, 104
 – surface marker of, 104, 108, 160, 417
 – ultrastructure of, 107
 – viral infectious DNA in, 483
 – viral related DNA sequences in, 559
- Leukemogenesis, mechanism of**, 435
- Leukoencephalopathy in childhood leukemia**, 31
- Lymphocytes**, see also B- and T-cells
 – antigens in, 338
 – B-
 – in vitro transformation by Abelson virus, 489
 – T-
 – cytotoxic, 370
 – helper, 369
 – suppressor, 369
- Lysosomal enzymes**,
 – degradation of Ig by, 407
- M-7**
 – contamination of human virus isolates with, 502
 – identical to C-type-virus, 502
- Macrophage**
 – activation of, by anti-AD755a serum, 478
 – α -naphthyl esterase in, 172
 – regulation of myelopoiesis by, 172
 – synthesis of CSF and PGE by, 172
 – suppressor, 173
 – tumor cell destruction by, 478
- Megakaryopoiesis in CML**, 61
- MER in immunotherapy**, 82
- 6-Mercaptopurine**

- treatment with, 101
- Methiolated polycytidylic acid, 145
 - effect of leukemic cells, 153
 - inhibition of RT by, 145, 150
 - structure of, 146
- Methotrexate
 - intermediate dose of, 115, 158
 - intrathecal, 30, 116
 - pharmacokinetics of, 140
 - toxicity of, 120
 - treatment with, 115
- Methylnitrosourea
 - induction of leukemia by, 225
- Microenvironment
 - influence on granulopoiesis by, 199
- Mixed leukocyte culture, 369
- Moloney leukemia virus
 - genetic transmission of, 561
 - infection with, 561
 - integration site for, 562, 569
 - locus to chromosome 6, 565
 - proviral DNA of, 570
- Moloney murine sarcoma virus (MSV), 425
- MOLT-4 leukemic cell line
 - expression of cALL antigen in, 341, 347, 362
- mRNA, translation of virus, 277
- Myelofibrosis
 - G-6-PD in, 57
 - histopathology of, 60
 - in myeloid metaplasia, 56
- Myelogenous leukemia, see AML
- Myeloid metaplasia, 56, 60
 - myelofibrosis in, 56
- Myeloid stem cell, see CFU-C
- Myeloperoxidase
 - in leukemic cells, 107
- Myelopoiesis
 - inhibition of, 173
 - regulation of, 171
- Neuramidase treated allogenic myeloblasts, 79
 - immunotherapy with, 81
- Nucleic acid biosynthesis
 - genes related to, 50
- Oligonucleotide
 - pppA2'p5'A2'p5'A
 - activation of nuclease by, 293
 - induction of synthesis of, by interferon, 292
 - T₁-
 - of C-type viruses, 241, 247, 248, 530, 550
- Oncogene, see also gen
 - viral, 524
- Oncogenesis, 425
 - model of, 525
- Oncorna virus, see also C-type virus
 - inactivation by human and primate complement, 501
- Orbital tumor associated reverse transcriptase, 498
- PAS reaction in leukemic cells, 102, 128
- Peroxidase, see also myeloperoxidase
 - in CFU-C, 213
- Philadelphia chromosome, 43, 45, 65, 195
- Phosphorylation in protein synthesis, 284
- Phytohemagglutinin stimulated lymphocytes
 - in immunotherapy, 86
- Plasma cells in CFU-C, 212
- Plasma clot cultures, 212
- Plasmids, 508, 513
 - genes, translocation of, 513
- Plasminogen activity
 - induction of, by Vitamin A, 320
- Pneumocystis carinii, 27, 31
 - in transplantation, 74
 - treatment of, 27
- Poland Syndrom, 39
- Polycythaemia vera
 - clonal origin of, 56
 - G-6-PD isoenzymes in, 56
 - histopathology of, 60
- PolyI-PolyC
 - stimulation of CSF production by, 173
- Prague Rous sarcoma virus
 - T1-oligonucleotides of, 550
- Prediction of therapeutic response in AML, 93
- Prednisolone
 - treatment with, 30, 100
- Prognostic factors
 - in leukemia, 27, 96, 99, 126, 127, 135
- Prostaglandines, 172
 - antagonists of, 172
 - inhibition of CFU-C proliferation by, 172
- Protein kinase
 - activation of, by interferon, 292, 330
 - activity in scr gene product, 264, 327, 425
 - of Friend leukemia cell inhibitor fractions, 288
 - inhibition of protein synthesis by, 289, 329
- Protein synthesis, 283
 - control of, 293
 - effect of hypertonic initiation block on, 298, 305
 - hemin-controlled repressor in, 284
 - inhibitor by interferon, 292
 - inhibition by protein kinase, 289
 - initiation of, 283
 - phosphorylation in, 284
- Proviral sequences in GaLV, 561
- Provirus
- Psychological studies in leukemic children, 27

- Radiation**
 – induced leukemia by, 8, 37
- Radioimmune precipitation assay, 388**
 – action of fetal calf serum in, 398
 – for C-type virus reactive human antibodies, 388, 396
- Rauscher leukemia virus**
 – antibodies in human sera against, 396
 – infection of bone marrow cultures with, 177
 – antisera, 402
- Receptor, surface**
 – for hormones in ALL, 165
 – for EBV, 237
- Recombination, illegitimate, 507, 515**
- Relaps**
 – leukemic, 76, 90, 119
- Remission**
 – in leukemia, 27, 82, 89, 119
- Retrovirus, 8 see also C-type virus**
 – genes, 424
 – human, 427
- Reverse transcriptase, 423**
 – enzymatic neutralizing activity for, 17
 – IgE directed against, 576
 – inhibition by MPC, 150
 – in an orbital tumor, 501
 – in primary chicken cells, 576
 – precursor of, 271
- Ribonucleotide pools in leukemic cells,**
- Rous sarcoma virus**
 – gene product of, 241, 425
 – RNA, in vitro translation of,
 – transforming gene of, 242
- Rubenstein-Tabi-Syndrom, 39**
- Rubidazone**
 – treatment in adult AML, 89, 157
- Sezary syndrom, 108**
 – cytology of, 109
- Simian sarcoma virus, 9, 425**
 – antibody against gp 70 of, 388
 – in human sera against, 385, 396
 – antisera, 402
 – endogenous human DNA fragment of, 555
 – fingerprint analysis of, 539
 – in human cells, 539, 553
- src-Gene, 327, see also gene and gene product**
- Stem cell, 191, see also CFU-S and CFU-C**
- Suppressor cell**
 – activity in immunotherapy, 86
- Supportive care**
 – in childhood ALL, 31
- Surface markers, see cell surface antigen**
 – antibody against gp 70 of, 388
 – antibody against in human sera, 385, 396
 – antisera, 402
 – endogenous human DNA fragment of, 555
 – fingerprint analyses of, 539
 – in human cells, 539, 553
- T-cell, 369**
 – antigen, 336, 349
 – in AML, 383, 419
 – culture, 381, 419
 – cytotoxic, 370
 – and EBV receptors, 238
 – response, 371
 – to HLA antigens, 370, 377
 – to leukemic antigens, 372, 379
- Teratocarcinoma**
 – cell surface antigen of, 582
 – cell hybrids with SV40-transformed fibroblasts, 581
- Terminal deoxynucleotidyl transferase**
 – in leukemia, 112, 125, 131, 160, 336
 – in normal tissues, 132
 – and response to therapy, 126
- Translation**
 – effect of HIB on, 298, 330
 – of monovalent ions on, 278, 295
 – of virus on, 279, 295
 – inhibition by Friend leukemia cell fractions, 287
 – of MC29 RNA in vitro, 255
 – of Rous sarcoma virus RNA in vitro, 271
 – of virus mRNAs in vitro, 277, 330
- Transfection**
 – with DNA of human leukemic cells, 484
- Transforming gen, 241, 261**
 – products, 257, 261
- Translocation, 44, 48**
- Transplantation**
 – autologous, 92, 158
 – of bone marrow, 71, 166
 – in leukemia, 74, 91, 166
- Transposable elements, 48, 514**
 – in bacterial plasmids, 519
 – in maize, 50
- Transposons, 513**
 – insertion, 517
 – lactose, 514
 – structure of, 518
- Treatment**
 – of ALL, 26, 30, 100, 117, 153, 164
 – of AML (ANLL), 89, 93, 153, 157, 164
 – with immunotherapy, 79, 165
 – with MPC, 153
- Tumor**
 – cell,
 – degradation of IgG by, 410
 – proteolytic enzymes in, 411
 – promoters, 527

- promoting of, by vitamin A, 32
- virus, see C-type virus,
- Tupaia
- continuous bone marrow culture of, 178
- Varicella-zoster in leukemia, 31

- Vincristine
- treatment with, 30, 100
- Viral
- antigens, expression of, in humoral immune response, 413
- DNA of human leukemic cells, transfection with, 484

- genes, endogenous, 424
- genome
 - Analysis of, 529
 - of BLV, 446
- RNA
 - characterization of, 530
 - fingerprint of, 532
- Vitamin A
- effect of plasminogen activator synthesis, 319
- effect on sarcoma gene expression, 321
- tumor promoting activity of, 322

Modern Trends in Human Leukemia II

Biological, Immunological, Therapeutical and Virological Aspects

Editors: R. Neth, R. C. Gallo, K. Mannweiler, W. C. Moloney

1976. 150 figures, 141 tables. XI, 576 pages (Haematology and Blood Transfusion, Volume 19)
ISBN 3-540-79785-8

Immunological Diagnosis of Leukemias and Lymphomas

International Symposium of the Institut für Hämatologie, GSF, October 28–30, 1976 – Neuherberg/Munich

Editors: S. Thierfelder, H. Rodt, E. Thiel

1977. 98 figures, 2 in color, 101 tables. X, 387 pages (Haematology and Blood Transfusion, Volume 20)
ISBN 3-540-08216-6

Unclassifiable Leukemias

Proceedings of a Symposium, held on October 11–13, 1974 at the Institute of Cell Pathology, Hôpital de Bicêtre, Paris, France

Editors: M. Bessis, G. Brecher

1975. 81 figures, 1 color-plate, 38 tables. VI, 270 pages (Monograph edition of the journal "Blood Cells", Volume 1, issue 1)
ISBN 3-540-07242-X

Hemopoietic Dysplasias

(Preleukemic States)

Proceedings of a Symposium held on October 11–13, 1974 at the Institute of Cell Pathology, Hôpital de Bicêtre, Paris, France

Editors: M. Bessis, G. Brecher

1977. 94 figures, 52 tables. 359 pages (Monograph edition of the journal "Blood Cells", Volume 2, issue 1/2)
ISBN 3-540-07597-6

H. Begemann, J. Rastetter

Atlas of Clinical Hematology

Initiated by L. Heilmeyer, H. Begemann
With contributions on the Ultrastructure of Blood Cells and their Precursors by D. Huhn and on Tropical Diseases by W. Mohr

Translated from the German by H. J. Hirsch

3rd, completely revised edition 1979. 228 figures, 194 in color, 12 tables. Approx. 290 pages
ISBN 3-540-09404-0

Distribution rights for Japan: Maruzen Co. Ltd., Tokyo

A. Polliack

Normal, Transformed and Leukemic Leukocytes

A Scanning Electron Microscopy Atlas

1977. 236 figures. IX, 140 pages
ISBN 3-540-08376-6

K. Lennert

Malignant Lymphomas

Other than Hodgkin's Disease

Histology–Cytology–Ultrastructure–Immunology

In collaboration with N. Mohri, H. Stein, E. Kaiserling, H.-K. Müller-Hermelink
Translated by F. D. Dallenbach, M. Soehring

1978. 287 figures (in 425 separate illustrations), 47 in color, 114 tables. XX, 833 pages (Handbuch der speziellen pathologischen Anatomie und Histologie, Band 1, Teil 3 B)
ISBN 3-540-08020-1



**Springer-Verlag
Berlin
Heidelberg
New York**

Zeitschrift
für die gesamte
Blutforschung

Blut

Organ der Deutschen Gesellschaft für Hämatologie und Onkologie
der Deutschen Gesellschaft für Bluttransfusion und Immunhämatologie
und der Österreichischen Gesellschaft für Hämatologie und Onkologie

ISSN 0006-5242

Title No. 277

Schriftleitung/Managing Editors

H. Heimpel, Ulm; D. Huhn, München; G. Ruhenstroth-Bauer, München;
W. Stich, München

Wissenschaftlicher Beirat/Advisory Board

H. Begemann, München; M. Bessis, Paris; K. Betke, München; I. Boll,
Berlin; H. Braunsteiner, Innsbruck; P. Dahr, Köln; E. Deutsch, Wien;
L. J. Dooren, Leiden; Th. M. Fliedner, Ulm; J. A. Forrester, London;
K. E. Gillert, Berlin; R. Gross, Köln; A. Hässig, Bern; S. Hollán, Budapest;
S.-A. Killmann, Kopenhagen; W. Laves, München; K. Lennert, Kiel;
H. Löffler, Gießen; G. Lucarelli, Pesaro; H. Nachtshiem, Boppard/Rhein;
H. Schmid-Schönbein, Aachen; H. G. Schwick, Marburg/L.; S. Seidl,
Frankfurt/M.; H. J. Senn, St. Gallen; W. Spielmann, Frankfurt/M.;
A. Stacher, Wien; F. Vogel, Heidelberg; H. D. Waller, Tübingen;
W. Willmanns, München

BLUT covers the whole spectrum of clinical and experimental haematology, including the fields of blood transfusion and haemostaseology. The official organ of the German Society for Haematology and Oncology, the German Society of Blood Transfusion and Immunohaematology, and the Austrian Society for Haematology and Oncology puts its main emphasis on clinical research and experimental research pertinent to problems of human blood disease. Devoted primarily to original articles and short communications, it also contains editorials and reviews designed to keep the reader up to date on all important new activities and developments in the field covered.

Information is presented on advances in adjacent disciplines, such as immunology, chemotherapy, radiotherapy, transplantation, genetics, and laboratory medicine. Founded in 1955, BLUT soon became the leading haematological journal in the German language. In the last decade, it has been changing into an international organ with more and more articles in English from many European and overseas countries. It is the belief of the editors that the common interests of clinical haematology, oncology, experimental haematology, haemostasis, and blood transfusion are still great enough today to justify a common source of information.

Subscription information and complimentary copy available upon request.

Please write to: Springer-Verlag
Wissenschaftliche Information Zeitschriften
Postfach 105 280
D-6900 Heidelberg 1



Springer-Verlag
Berlin
Heidelberg
New York